中国组织工程研究 ›› 2018, Vol. 22 ›› Issue (21): 3401-3409.doi: 10.3969/j.issn.2095-4344.0520
• 干细胞综述 stem cell review • 上一篇 下一篇
姚 茜1,韦正波1,谢 莹2
修回日期:
2018-03-29
出版日期:
2018-07-28
发布日期:
2018-07-28
通讯作者:
韦正波,博士,主任医师,广西医科大学附属肿瘤医院,广西壮族自治区南宁市 530021;
责任通讯作者:谢莹,博士,教授,广西医科大学生命科学研究院,广西区域性高发肿瘤早期防治研究教育部重点实验室,广西壮族自治区南宁市 530021
作者简介:
姚茜,女,1989年生,湖北省洪湖市人,蒙古族,广西医科大学在读硕士,主要从事肿瘤干细胞及相关研究。
基金资助:
国家自然科学基金项目(81460415,81760361);广西自然科学基金项目(2017GXNSFAA198064,2016GXNSFAA380096)
Yao Xi1, Wei Zheng-bo1, Xie Ying2
Revised:
2018-03-29
Online:
2018-07-28
Published:
2018-07-28
Contact:
Wei Zheng-bo, M.D., Chief physician, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China;
Xie Ying, M.D., Professor, Life Science Institute, Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
About author:
Yao Xi, Master candidate, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Supported by:
the National Natural Science Foundation of China, No. 81460415, 81760361; Guangxi Natural Science Foundation of China, No. 2017GXNSFAA198064, 2016GXNSFAA380096
摘要:
文章快速阅读:
文题释义: 鼻咽癌干细胞:鼻咽癌组织中存在具有干细胞样特性的一小部分细胞,控制着肿瘤发生发展的整个过程,与鼻咽癌转移、复发和对放化疗抵抗密切相关,是影响患者预后的重要因素。 鼻咽癌干细胞靶向治疗:鼻咽癌干细胞作为鼻咽癌发生发展过程的关键因素,若能找到直接靶向鼻咽癌干细胞的药物或方法,将为从根本上消除鼻咽癌干细胞提供可能,从而在理论上可以达到控制甚至治愈鼻咽癌的目的。
中图分类号:
姚 茜,韦正波,谢 莹 . 鼻咽癌干细胞研究:表面标志物、发生发展机制及靶向治疗[J]. 中国组织工程研究, 2018, 22(21): 3401-3409.
Yao Xi, Wei Zheng-bo, Xie Ying. Nasopharyngeal carcinoma stem cells: surface markers, occurrence and development mechanisms, and targeted therapy[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(21): 3401-3409.
早在2007年Wang等[14]就已经利用侧群细胞可将进入细胞核的DNA荧光染料hoechst33342排出细胞外的特征,首次通过流式细胞仪从5种不同亚型的鼻咽癌细胞株中分离出非侧群细胞和侧群细胞,并同时进行体内和体外实验。结果发现在不同亚型的鼻咽癌细胞株中均存在侧群细胞,且侧群细胞还具有增殖、分化和自我更新等一系列干细胞特性。而当将这两种细胞分别接种到非肥胖糖尿病/重症联合免疫缺陷(NOD/SCID)小鼠体内进行成瘤实验时,侧群细胞还表现出很强的致瘤性。
2.4 鼻咽癌肿瘤干细胞靶向治疗前景与展望 不管是对鼻咽癌肿瘤干细胞分选鉴定还是分子作用机制的研究都是为了更好的了解鼻咽癌发生、发展的全过程,以寻找更为有效的临床治疗方案来控制或改善鼻咽癌。就目前来说,放化疗仍是公认的最为有效的鼻咽癌治疗手段,但治疗后中晚期患者预后仍不理想,而鼻咽癌肿瘤干细胞的发现为鼻咽癌的治疗提供了新的思路。目前仅在白血病的临床治疗上有专门针对白血病干细胞的靶向药物,而鼻咽癌肿瘤干细胞靶向治疗还尚处于研究阶段,尽管如此,随着近些年对其表面标记物及其信号通路研究的深入,不断有学者筛选出新的肿瘤干细胞标志物,对肿瘤干细胞相关信号通路也有许多新的发现,这为针对鼻咽癌肿瘤干细胞的靶向治疗打下了坚实的基础。另外,近些年还有新的观点认为鼻咽癌肿瘤干细胞与鼻咽癌微环境及上皮-间质转化过程有关,且鼻咽癌肿瘤干细胞的相关信号通路之间还存在着相互交叉作用的关系,但具体机制仍不十分明确。因此弄清这些机制对于进一步阐明鼻咽癌发生、发展过程以及寻找新的有效治疗方案具有重大的意义,是今后研究的方向。
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.[2] 梁锌,杨剑,高婷,等. 中国鼻咽癌流行概况[J]. 中国肿瘤, 2016, 25(11):835-840.[3] Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11): 1509-1520.[4] Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009; 138(5):822-829.[5] O'Connor ML, Xiang D, Shigdar S, et al. Cancer stem cells: A contentious hypothesis now moving forward. Cancer Lett. 2014;344(2):180-187.[6] Tirino V, Desiderio V, Paino F, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 2013;27(1):13-24.[7] Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760.[8] Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008; 26(17):2839-2845.[9] Xie P, Yang JP, Cao Y, et al. Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target. Cell Death Dis. 2017;8(6):e2834.[10] Kakarala M, Wicha MS. Cancer stem cells: implications for cancer treatment and prevention. Cancer J. 2007;13(5): 271-275.[11] Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737.[12] Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983-3988.[13] Mannelli G, Gallo O. Cancer stem cells hypothesis and stem cells in head and neck cancers. Cancer Treat Rev. 2012;38(5): 515-539.[14] Wang J, Guo LP, Chen LZ, et al. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007;67(8):3716-3724.[15] Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017;16(1):41.[16] Liao K, Xia B, Zhuang QY, et al. Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-κB/COX-2 pathway. Theranostics. 2015;5(3):302-321.[17] Gerweck LE, Wakimoto H. At the Crossroads of Cancer Stem Cells, Radiation Biology, and Radiation Oncology. Cancer Res. 2016;76(5):994-998.[18] Hauswirth AW, Florian S, Printz D, et al. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest. 2007;37(1):73-82.[19] Song K, Kwon H, Han C, et al. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122. Oncotarget. 2015;6(38):40822-40835.[20] Chen WC, Chang YS, Hsu HP, et al. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Oncotarget. 2015;6(40):42923-42937.[21] Zhang J, Jiao J, Cermelli S, et al. miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer Res. 2015; 75(9):1859-1867.[22] Elbasateeny SS, Salem AA, Abdelsalam WA, et al. Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer. Pathol Res Pract. 2016;212(1):10-16.[23] Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401.[24] Suetsugu A, Nagaki M, Aoki H, et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351(4):820-824.[25] Jang JW, Song Y, Kim SH, et al. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma. Cancer Lett. 2017;389:1-10.[26] Chu P, Clanton DJ, Snipas TS, et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer. 2009;124(6):1312-1321.[27] Hori Y, Fukumoto M, Kuroda Y. Enrichment of putative pancreatic progenitor cells from mice by sorting for prominin1 (CD133) and platelet-derived growth factor receptor beta. Stem Cells. 2008;26(11):2912-2920.[28] Cioffi M, D'Alterio C, Camerlingo R, et al. Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer. Sci Rep. 2015;5:10357.[29] Zhuang HW, Mo TT, Hou WJ, et al. Biological characteristics of CD133(+) cells in nasopharyngeal carcinoma. Oncol Rep. 2013;30(1):57-63.[30] Jiang Q, Zhang Q, Wang S, et al. A Fraction of CD133+ CNE2 Cells Is Made of Giant Cancer Cells with Morphological Evidence of Asymmetric Mitosis. J Cancer. 2015;6(12): 1236-1244.[31] Su J, Xu XH, Huang Q, et al. Identification of cancer stem-like CD44+ cells in human nasopharyngeal carcinoma cell line. Arch Med Res. 2011;42(1):15-21.[32] Lun SW, Cheung ST, Cheung PF, et al. CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma. PLoS One. 2012;7(12):e52426.[33] Janisiewicz AM, Shin JH, Murillo-Sauca O, et al. CD44(+) cells have cancer stem cell-like properties in nasopharyngeal carcinoma. Int Forum Allergy Rhinol. 2012;2(6):465-470.[34] Xu X, Liu Y, Su J, et al. Downregulation of Bmi-1 is associated with suppressed tumorigenesis and induced apoptosis in CD44? nasopharyngeal carcinoma cancer stem-like cells. Oncol Rep. 2016;35(2):923-931.[35] Shen YA, Wang CY, Chuang HY, et al. CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation. Oncotarget. 2016;7(36):58351-58366.[36] Yang CH, Wang HL, Lin YS, et al. Identification of CD24 as a cancer stem cell marker in human nasopharyngeal carcinoma. PLoS One. 2014;9(6):e99412.[37] Yu F, Sim AC, Li C, et al. Identification of a subpopulation of nasopharyngeal carcinoma cells with cancer stem-like cell properties by high aldehyde dehydrogenase activity. Laryngoscope. 2013;123(8):1903-1911.[38] Wu A, Luo W, Zhang Q, et al. Aldehyde dehydrogenase 1, a functional marker for identifying cancer stem cells in human nasopharyngeal carcinoma. Cancer Lett. 2013;330(2):181-189.[39] Luo WR, Yao KT. Cancer stem cell characteristics, ALDH1 expression in the invasive front of nasopharyngeal carcinoma. Virchows Arch. 2014;464(1):35-43.[40] Luo WR, Gao F, Li SY, et al. Tumour budding and the expression of cancer stem cell marker aldehyde dehydrogenase 1 in nasopharyngeal carcinoma. Histopathology. 2012;61(6):1072-1081.[41] Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95(26):15665-15670.[42] Zhang H, Liu W, Feng X, et al. Identification of ABCG2? cells in nasopharyngeal carcinoma cells. Oncol Rep. 2012;27(4): 1177-1187.[43] Xu L, Huang TJ, Hu H, et al. The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma. Cancer Lett. 2017 Oct 27. [Epub ahead of print][44] Guan GF, Zhang DJ, Zheng Y, et al. Abnormal Wnt signaling and overexpression of ABCG2 contributes to drug efflux properties of side population cells in nasopharyngeal carcinoma. Mol Med Rep. 2015;12(3):4352-4357.[45] Zheng D, Liao S, Zhu G, et al. CD38 is a putative functional marker for side population cells in human nasopharyngeal carcinoma cell lines. Mol Carcinog. 2016;55(3):300-311.[46] Lun SW, Cheung ST, Lo KW. Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. Chin J Cancer. 2014;33(11):529-538.[47] Jia W, Ren C, Wang L, et al. CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX. Oncotarget. 2016;7(34):55328-55342.[48] Peng S, Wu C, Sun W, et al. Snail-mediated cancer stem cell-like phenotype in human CNE2 nasopharyngeal carcinoma cell. Head Neck. 2018;40(3):485-497.[49] Zou ZW, Ma C, Medoro L, et al. LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells. Oncotarget. 2016;7(38):61741-61754.[50] Lichtenauer UD, Shapiro I, Geiger K, et al. Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. Endocrinology. 2008;149(3):1314-1322.[51] Hoe SL, Tan LP, Jamal J, et al. Evaluation of stem-like side population cells in a recurrent nasopharyngeal carcinoma cell line. Cancer Cell Int. 2014;14(1):101.[52] Peng Y, He G, Tang D, et al. Lovastatin Inhibits Cancer Stem Cells and Sensitizes to Chemo- and Photodynamic Therapy in Nasopharyngeal Carcinoma. J Cancer. 2017;8(9):1655-1664.[53] Wen Y, Hou Y, Huang Z, et al. SOX2 is required to maintain cancer stem cells in ovarian cancer. Cancer Sci. 2017;108(4): 719-731.[54] Barton VN, Christenson JL, Gordon MA, et al. Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. Cancer Res. 2017;77(13):3455-3466.[55] Liu P, Zhang R, Yu W, et al. FGF1 and IGF1-conditioned 3D culture system promoted the amplification and cancer stemness of lung cancer cells. Biomaterials. 2017;149:63-76.[56] Jiang QP, Yao KT. Isolation and detection of label-retaining cells in a nasopharyngeal carcinoma cell line. Chin J Cancer. 2010;29(5):572-574.[57] Li L, Zhang Y, Fan Y, et al. Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics. 2015;7(2):155-173.[58] Cheng Y, Cheung AK, Ko JM, et al. Physiological β-catenin signaling controls self-renewal networks and generation of stem-like cells from nasopharyngeal carcinoma. BMC Cell Biol. 2013;14:44.[59] Cheng Y, Phoon YP, Jin X, et al. Wnt-C59 arrests stemness and suppresses growth of nasopharyngeal carcinoma in mice by inhibiting the Wnt pathway in the tumor microenvironment. Oncotarget. 2015;6(16):14428-14439.[60] Jiang R, Niu X, Huang Y, et al. β-Catenin is important for cancer stem cell generation and tumorigenic activity in nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai). 2016;48(3):229-237.[61] Wang W, Yi M, Chen S, et al. NOR1 Suppresses Cancer Stem-Like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 Signal Circuit. J Cell Physiol. 2017;232(10):2829-2840.[62] Li YY, Chung GT, Lui VW, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat Commun. 2017;8:14121.[63] Zheng Z, Qu JQ, Yi HM, et al. MiR-125b regulates proliferation and apoptosis of nasopharyngeal carcinoma by targeting A20/NF-κB signaling pathway. Cell Death Dis. 2017; 8(6):e2855.[64] Li LN, Xiao T, Yi HM, et al. MiR-125b Increases Nasopharyngeal Carcinoma Radioresistance by Targeting A20/NF-κB Signaling Pathway. Mol Cancer Ther. 2017;16(10):2094-2106.[65] Kuang CM, Fu X, Hua YJ, et al. BST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer. Cell Death Dis. 2017;8(6):e2874.[66] Wu SL, Li YJ, Liao K, et al. 2-Methoxyestradiol inhibits the proliferation and migration and reduces the radioresistance of nasopharyngeal carcinoma CNE-2 stem cells via NF-κB/HIF-1 signaling pathway inactivation and EMT reversal. Oncol Rep. 2017;37(2):793-802.[67] Yi M, Cai J, Li J, et al. Rediscovery of NF-κB signaling in nasopharyngeal carcinoma: How genetic defects of NF-κB pathway interplay with EBV in driving oncogenesis. J Cell Physiol. 2017 Dec 21. doi: 10.1002/jcp.26410. [Epub ahead of print][68] Hou Y, Feng S, Wang L, et al. Inhibition of Notch-1 pathway is involved in rottlerin-induced tumor suppressive function in nasopharyngeal carcinoma cells. Oncotarget. 2017;8(37): 62120-62130.[69] Yu S, Zhang R, Liu F, et al. Notch inhibition suppresses nasopharyngeal carcinoma by depleting cancer stem-like side population cells. Oncol Rep. 2012;28(2):561-566.[70] Port RJ, Pinheiro-Maia S, Hu C, et al. Epstein-Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells. J Pathol. 2013;231 (3):367-377.[71] Liu T, Sun Q, Li Q, et al. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Mol Cancer Ther. 2015;14(2):429-439.[72] Zhao M, Luo R, Liu Y, et al. miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. Nat Commun. 2016;7:11309.[73] Zhang Y, Lin R, Zhang Z, et al. Activation of mTOR signaling pathway in cancer stem cells of nasopharyngeal carcinoma and inhibitive effect of rapamycin against the cancer stem cells. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015; 29(13):1179-1184.[74] Yang C, Zhang Y, Zhang Y, et al. Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma. Int J Oncol. 2015; 47(3):909-917.[75] Wang Z, Luo F, Li L, et al. STAT3 activation induced by Epstein-Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 And ERK signaling. Eur J Cancer. 2010;46(16):2996-3006.[76] Zhong Q, Liu ZH, Lin ZR, et al. The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res. 2018;24(3):659-673. |
[1] | 林清凡, 解一新, 陈婉清, 叶振忠, 陈幼芳. 人胎盘源间充质干细胞条件培养液可上调缺氧状态下BeWo细胞活力和紧密连接因子的表达[J]. 中国组织工程研究, 2021, 25(在线): 4970-4975. |
[2] | 蒲 锐, 陈子扬, 袁凌燕. 不同细胞来源外泌体保护心脏的特点与效应[J]. 中国组织工程研究, 2021, 25(在线): 1-. |
[3] | 袁家威, 张海涛, 揭 珂, 曹厚然, 曾意荣. 基于网络药理学研究桃红四物汤治疗假体周围感染的潜在靶点和机制[J]. 中国组织工程研究, 2021, 25(9): 1428-1433. |
[4] | 张秀梅, 翟运开, 赵 杰, 赵 萌. 类器官模型国内外数据库近10年文献研究热点分析[J]. 中国组织工程研究, 2021, 25(8): 1249-1255. |
[5] | 王正东, 黄 娜, 陈婧娴, 郑作兵, 胡鑫宇, 李 梅, 苏 晓, 苏学森, 颜 南. 丁酸钠抑制氟中毒可诱导小胶质细胞活化及炎症因子表达增多[J]. 中国组织工程研究, 2021, 25(7): 1075-1080. |
[6] | 汪显耀, 关亚琳, 刘忠山. 提高间充质干细胞治疗难愈性创面的策略[J]. 中国组织工程研究, 2021, 25(7): 1081-1087. |
[7] | 万 然, 史 旭, 刘京松, 王岩松. 间充质干细胞分泌组治疗脊髓损伤的研究进展[J]. 中国组织工程研究, 2021, 25(7): 1088-1095. |
[8] | 廖成成, 安家兴, 谭张雪, 王 倩, 刘建国. 口腔鳞状细胞癌干细胞的治疗靶点及应用前景[J]. 中国组织工程研究, 2021, 25(7): 1096-1103. |
[9] | 谢文佳, 夏天娇, 周卿云, 刘羽佳, 顾小萍. 小胶质细胞介导神经元损伤在神经退行性疾病中的作用[J]. 中国组织工程研究, 2021, 25(7): 1109-1115. |
[10] | 李珊珊, 郭笑霄, 尤 冉, 杨秀芬, 赵 露, 陈 曦, 王艳玲. 感光细胞替代治疗视网膜变性疾病[J]. 中国组织工程研究, 2021, 25(7): 1116-1121. |
[11] | 焦 慧, 张一宁, 宋雨晴, 林 宇, 王秀丽. 乳腺癌类器官研究进展及临床应用前景[J]. 中国组织工程研究, 2021, 25(7): 1122-1128. |
[12] | 王诗琦, 张金生. 中医药调控缺血缺氧微环境对骨髓间充质干细胞增殖、分化及衰老的影响[J]. 中国组织工程研究, 2021, 25(7): 1129-1134. |
[13] | 曾燕华, 郝延磊. 许旺细胞体外培养及纯化的系统性综述[J]. 中国组织工程研究, 2021, 25(7): 1135-1141. |
[14] | 孔德胜, 何晶晶, 冯宝峰, 郭瑞云, Asiamah Ernest Amponsah, 吕 飞, 张舒涵, 张晓琳, 马 隽, 崔慧先. 间充质干细胞修复大动物模型脊髓损伤疗效评价的Meta分析[J]. 中国组织工程研究, 2021, 25(7): 1142-1148. |
[15] | 侯婧瑛, 于萌蕾, 郭天柱, 龙会宝, 吴 浩. 缺氧预处理激活HIF-1α/MALAT1/VEGFA通路促进骨髓间充质干细胞生存和血管再生[J]. 中国组织工程研究, 2021, 25(7): 985-990. |
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||